ã¡ãã£ã¢èšäº
第äžäžå
± ã³ããã¯ã¯ã㳠幎å
ã«ãæ°å人èŠæš¡ã®èšåºè©Šéšå®æœãž
ããºãææ°ããŒã¯ 505
twitterã³ã¡ã³ã 256ä»¶äž 1ïœ100件
æ¥å¹Žä»¥éã«æ¥çš®ããå Žåã¯ãã¡ããæåãªéžæè¢ã«ãªãããã§ãã
第äžäžå
±ãæ±å€§å»ç§ç ãšå
±åéçºããæäžå
±ãŠã€ã«ã¹ã¯ã¯ãã³ã¯mRNAã¯ã¯ãã³ã第â
¢çžæ²»éšã®æ瞟ãè¯ããã°ãåã¿ã€ãã®ã¯ã¯ãã³ãšããŠãäžççã«ïŒçªç®ã®ç»å Ž
mRNAã¯ã¯ãã³ãªããããã
ïœRNAã®ã¿ã«æãã®ãªããäžå¿ã第äžäžå
±ã®ã¯ã¯ãã³ã幎æããããã«ã¯ãã©ãç«ã¡ããã§ããã©ãã
ãã®åã«ä»çš®ã®å¡©é矩ã»ã¢ã³ãžã§ã¹ãäžã«åºããã§ãããæµç³ã«åŸçºã§ãããåœå ã¯ã¯ãã³ã¯æ¢ç¥ã®å€ç°çš®ã«ã¯å¯Ÿå¿ããŠããã§ããããã
ãã®åã«ä»çš®ã®å¡©é矩ã»ã¢ã³ãžã§ã¹ãäžã«åºããã§ãããæµç³ã«åŸçºã§ãããåœå ã¯ã¯ãã³ã¯æ¢ç¥ã®å€ç°çš®ã«ã¯å¯Ÿå¿ããŠããã§ããããã
é 匵ã£ãŠïŒïŒãé¡ãïŒïŒ
幎å
ã«èšåºè©ŠéšïŒïŒåšåé
ãã§ã¯ã
ãéå£æ§è©ŠéšããªããŠã®ãããã®ã ::
ãæ°åã³ãããŠã€ã«ã¹ã§ã¯ãã§ã«å¹æã確èªãããã¯ã¯ãã³ãããããšãããè©Šéšã®ããã«åœã®è¬ãæäžããããšã¯å«ççãªåé¡ããããšãããåœéçã«ãåŸçºã®ã¯ã¯ãã³éçºã®èª²é¡ãšãªã£ãŠããŸãããã®ããâã
ã»COVID-19â
æ¿åºãé æäŸåºãšååŒåæ¢ãã®äŸé Œæ€åãž é 販äºæ¥è ã« ããã
Satoki
æ¿åºãé æäŸåºãšååŒåæ¢ãã®äŸé Œæ€åãž é 販äºæ¥è ã« ããã
Satoki
ïœRNAã¯ã¯ãã³ã§ãç¬ãã¥ã¢ããã¯ç€Ÿã®ãã®ã¯äºé²å¹æïŒïŒïŒ
æ¢ãŸãã ã£ãã®ã§å¿
ãããŒããšããèš³ã§ã¯ãªãã®ã§æ³šæã
ãžãŒïœå¡©é矩以å€ããã£ããã åœå
ã¯ã¯ãã³ïœ ïŒåœå
ã®äŒæ¥ã®ã¯ã¯ãã³éçºã«ã€ããŠã¯ããã®ã»ããã€ãªãã³ãã£ãŒã®ã¢ã³ãžã§ã¹ãå¡©é矩補è¬ã補è¬äŒç€Ÿã®KMãã€ãªããžã¯ã¹ãããããèšåºè©Šéšãå§ã㊠第äžäžå
± ã³ããã¯ã¯ã㳠幎å
ã«ãæ°å人èŠæš¡ã®èšåºè©Šéšå®æœãž
mRNAã¯ã¯ãã³ãå®çšåã§ãããšåãã£ããè¿œéã§ããçšåºŠã®éçºåã¯åœå
ã«ãã£ããšããã®ã¯å¥œææ
第äžäžå
±ã®ã¯ã¯ãã³ã¯ããã«ã¿æ ªãã«ãå¹æã®é«ããã®ã«ããŠæ¬²ããã§ããã
ã
ã
ç 究宀ã®åæãæºãã£ãŠããä»äºã
ããã°ããŒïŒãã®ããåæïŒ
ããã°ããŒïŒãã®ããåæïŒ
第äžäžå
±ã®ã³ããã¯ã¯ãã³ã幎å
ã«ãèšåºè©Šéšãå§ãããšããããšãåãããŸããã
ãã®èšäºãåãšåãããšã§ããããã£ãããšèšåºè©Šéšãè¡ã£ãäžã§åœæ°ã䜿çšã§ããããã«ããŠã»ããã§ããã
ãã®èšäºãåãšåãããšã§ããããã£ãããšèšåºè©Šéšãè¡ã£ãäžã§åœæ°ã䜿çšã§ããããã«ããŠã»ããã§ããã
åœç£ã®ãmRNAã¯ã¯ãã³ã
åºæ¥ãã°åœç£ã¯ã¯ãã³æã¡ãããããã³ã¬ãè¯ããªãâŠ
第äžäžå
±ã¯ãã¡ã€ã¶ãŒãã¢ãã«ãåæ§ãmRNAã
ã§ããã
ã·ãªãã®ç€Ÿé·ã¯æéã¯ããããå®å šæ§ãéºäŒåçµæãããæåæäžããšã®ããšã§ãããå©å®³é¢ä¿è ã§ã¯ãªãå°é家ã®ç¥èŠãåŸ ã¡ãããšæããŸãã
ã§ããã
ã·ãªãã®ç€Ÿé·ã¯æéã¯ããããå®å šæ§ãéºäŒåçµæãããæåæäžããšã®ããšã§ãããå©å®³é¢ä¿è ã§ã¯ãªãå°é家ã®ç¥èŠãåŸ ã¡ãããšæããŸãã
"æ²»éšã®çºã¯ã¯ãã³ãå«ãŸããŠããªãåœè¬ãæ°äžäººã«æäžããŠå¹æãæ¯èŒãã倧èŠæš¡èšåºè©Šéšã¯å«ççã«é£ãããããæ¥çš®åŸã®æäœå€ãå
çºã¯ã¯ãã³ãšæ¯ã¹ãŠéè²ããªãããšã確èªãããéå£æ§è©Šéšããæ€èš"
åœè¬ã䜿ããªãèšåºè©Šéšæ¹æ³ãªããŠããã®ããã§ãåŸæ¥ã®æ¹æ³ã§ãªãæ¹æ³ã§æ¬åœã«å®å
šæ§ã確èªã§ããã®ããŸãæ°ããåé¡ãåºãŠãããæ°çºã¯ã¯ãã³ã¯å³ãããªãŒã
éçºäžã®ã¯ã¯ãã³ãæäžãã人ã®æäœã®å€ããã§ã«å®çšåãããã¯ã¯ãã³ãšæ¯ã¹ãŠéè²ããªãããšã確èªãããéå£æ§è©Šéšããšããæ¹æ³ã§æ€èšããŠãããšããããšã§ãã
åœç£ã®ãmRNAã¯ã¯ãã³ããã
åœç£mRNAã¯ã¯ãã³ãã€ãã«ããã
æµ·å€è£œå¿é¿ã®äººãããããšã ãåœç£ã¯ã¯ãã³ã§éžæè¢ãå¢ããã®ã¯è¯ãããšãéæ¿ãªåã¯ã¯ãã³æŽŸãå·¥å Žç Žå£ãšãããŸããããã«
ã第äžäžå
±ã åœç£ã®mRNAã¯ã¯ãã³ã幎å
ã«ãæ°å人èŠæš¡ã®èšåºè©Šéšå®æœãž
2
ç°èè ãªã®ã§ããã§ããã§ã
1æ¥ãã³ãšããããéããªãéçå°ã§
æ¥ãå¿ èŠãªã
88
>2
ãã³ãã³ããã«ãªãå®æ
653
>2
ã¬ãæ§ãå®ãããã«ãã£ããã¯ã¯ãã³ãïŒ
2
ç°èè ãªã®ã§ããã§ããã§ã
1æ¥ãã³ãšããããéããªãéçå°ã§
æ¥ãå¿ èŠãªã
88
>2
ãã³ãã³ããã«ãªãå®æ
653
>2
ã¬ãæ§ãå®ãããã«ãã£ããã¯ã¯ãã³ãïŒ
ååŽçã®å€ãäœè³ªãšè³éãªãœãŒã¹ã®ç¡ãã§åœç£ã¯ã¯ãã³éçºãé
ããŠããã®ã¯å€§åé¡ã ãè²ã
足䞊ã¿ãæã£ãŠãããåæã«ã€ãã«ã¡ã¯ãã³ãå§ããšããäžçã§ãã§ã«æŠæŒ¢ã³ããæ²»çã«äœ¿çšãããæ¥æ¬äººãéçºããæ²»çè¬ã®èªå¯ã
åœç£ã¯ã¯ãã³å¹Žå ã«ãæ°å人èŠæš¡ã®èšåºè©Šéšå®æœãž
åœç£ã¯ã¯ãã³å¹Žå ã«ãæ°å人èŠæš¡ã®èšåºè©Šéšå®æœãž
åå·äŒæ¥ããïŒïŒïŒ
mRNA
mRNA
>第äžäžå
±ã¯ãåœç£ã®ãmRNAã¯ã¯ãã³ãã®æ°å人èŠæš¡ã®èšåºè©Šéšã幎å
ã«ãå®æœããæ¹åã§æºåãé²ããŠããããšãåãããŸããã
åœå
ã®åã¯ã¯ãã³æŽŸã¯ãmRNAã¯ã¯ãã³ã ããå±éºããšèšŽãã人ãå€ããã
ãããã®äººã ã¯åœç£ã§ããã¡ãªãã ãããªã
ç§ã¯åœå æ²»éšã§æå¹æ§ã確èªãããããšãæåŸ ãåœç£ãžã®åãæ¿ãã¯éèŠ
ãããã®äººã ã¯åœç£ã§ããã¡ãªãã ãããªã
ç§ã¯åœå æ²»éšã§æå¹æ§ã確èªãããããšãæåŸ ãåœç£ãžã®åãæ¿ãã¯éèŠ
ã¡ãããšããŠãæ¹ã®åœç£ã¯ã¯ãã³
æ²»éšã§å®å
šæ§ãå¯åå¿ã®ç¶æ
ãªã©ããŒã¿ããŸãšãã€ã€ãæ©æã«æ¿èªãè¡ã£ãŠãå®çšåããŠã»ãã
å€åœè£œãããåœç£ã¯ã¯ãã³ã®æ¹ãå®å¿ã§ãããã ãã»ã»ã»
å€åœè£œãããåœç£ã¯ã¯ãã³ã®æ¹ãå®å¿ã§ãããã ãã»ã»ã»
ãæ°åã³ãããŠã€ã«ã¹ã§ã¯ãã§ã«å¹æã確èªãããã¯ã¯ãã³ãããããšãããè©Šéšã®ããã«åœã®è¬ãæäžããããšã¯å«ççãªåé¡ãããã
ã ããªããäºéç²æ€æ³ä»¥å€ã®æ²»éšæ³ãåããŠç¥ã£ãã
ã ããªããäºéç²æ€æ³ä»¥å€ã®æ²»éšæ³ãåããŠç¥ã£ãã
ä»åŸãæ°ããã³ããã¯ã¯ãã³ã®èšåºè©Šéšã¯æ¬åœã«é£ããããæ€èšãããŠããæäœäŸ¡ã§ã®éå£æ§è©Šéšã¯ããªãçŸå®çãªè·¯ç·ã§ã¯ãããã©ãæ°äžäººã§çºçäºé²å¹æãçŽæ¥èª¿ã¹ãè©Šéšãšæ¯ã¹ããšã©ãããŠãèŠå£ãããããã
ä»ãªããŸã ã¯ã¯ãã³æ¥çš®ã§ããªã人ã¯ããªããããå ±é
¬æ¬¡ç¬¬ã§ã¯æ²»éšã«åå ãã人ãçµæ§ç¢ºä¿ã§ãããã ãã©ãªãæ²»éšçµäºåŸã«çµæãæããŠããããã°å¿
èŠã«å¿ããŠãã¡ã€ã¶ãŒãã¢ãã«ããæ¥çš®ããã°è¯ãããã ãã
éå£æ§è©Šéšãå³ãããã ãã©èª å®ã§ã¯ãããçµæãã¡ã§ãç¡é§ã«ã¯ãªãããšæãã
æäœã®å€ã§å¹æã¯ããçšåºŠãããã®ã ãããã©ãå®å
šæ§ã¯ã©ã®ããã«è©äŸ¡ãããã ããïŒ
äœåŠãã®è£œè¬ãšã¯åãéãã§ïŒ
äœã§åœç£ãŸã§mRNAãªã®ïŒ
ãããåœããåã§ãèŠå¶ã®ã¿ã¬ãå€ããå¥åº·é£åã«ä»ãåãããã«ãå»è¬åãå¥åº·é£ååããã®ã¯èããããªãã
æ¥å¹Žã¯å¡©é矩ã第äžäžå
±ããã®èŸºã®ã¯ã¯ãã³æãŠã°è¯ãããªãã
ã¯ã¯ãã³åé¡ãæ©ã«ãç§åŠç 究å
šè¬ã®äŸ¡å€ãèŠçŽãããŠæ¬²ããã®ã ãâŠãè³æºã®ä¹ããæãåœã§ãéžæãšéäžããã ãŒã³ã·ã§ããããåœããå®ããã ãè²·ãã°ããããšãããã®èªæ®ºè¡çºã§ãããªãã
ã¢ã³ãžã§ã¹
å¡©é矩
第äžäžå ±
KMãã€ãª
å¡©é矩
第äžäžå ±
KMãã€ãª
æ°åã³ããðŠ ã§ã¯ãã§ã«å®çšåãããã¯ã¯ãã³ãããããšãããåœè¬ãæ°äžäººã«æäžããŠå¹æãæ¯èŒãã倧èŠæš¡èšåºè©Šéšã¯å«ççã«é£ããâŠäŒç€Ÿã§ã¯éçºäžã®ã¯ã¯ãã³ãæäžãã人ã®æäœå€ããã§ã«å®çšåãããã¯ã¯ãã³ãšæ¯ã¹ãŠéè²ããªãããšã確èªãããéå£æ§è©Šéšããšããæ¹æ³âŠ
åœç£ã¯ã¯ãã³ãé 匵ãã
第äžäžå
± mRNAã¯ã¯ã㳠幎å
ã«ãæ°å人èŠæš¡ã®èšåºè©Šéšå®æœ
2021幎7æ12æ¥
éçºäžã®ã¯ã¯ãã³ãæäžãã人ã®æäœã®å€ããã§ã«å®çšåãããã¯ã¯ãã³ãšæ¯ã¹ãŠéè²ããªãããšã確èªãããéå£æ§è©Šéšããšããæ¹æ³ã§æ€èš
æ¿èªãããã°ãåŒççã«ããå·¥å Žã§å€§éçç£ãè¡ã
2021幎7æ12æ¥
éçºäžã®ã¯ã¯ãã³ãæäžãã人ã®æäœã®å€ããã§ã«å®çšåãããã¯ã¯ãã³ãšæ¯ã¹ãŠéè²ããªãããšã確èªãããéå£æ§è©Šéšããšããæ¹æ³ã§æ€èš
æ¿èªãããã°ãåŒççã«ããå·¥å Žã§å€§éçç£ãè¡ã
第äžäžå
±ã¯mRNAã¯ã¯ãã³ãªã®ã
ãæ°åã³ãããŠã€ã«ã¹ã§ã¯ãã§ã«å¹æã確èªãããã¯ã¯ãã³ãããããšãããè©Šéšã®ããã«åœã®è¬ãæäžããããšã¯å«ççãªåé¡ããããšãããåœéçã«ãåŸçºã®ã¯ã¯ãã³éçºã®èª²é¡ãâ
壮倧ãªç¡é§æéç¬ç¬ç¬
幎å
ãŠé 調ãªãåžæè
ã¯ã»ãŒã¯ã¯ãã³æ¥çš®æžã¿ã®ã¯ãã§ãæªæ¥çš®ã®è¢«éšè
ãæ°å人ãéãããããã ãããïŒ
âäŒç€Ÿã§ã¯éçºäžã®ã¯ã¯ãã³ãæäžãã人ã®æäœã®å€ããã§ã«å®çšåãããã¯ã¯ãã³ãšæ¯ã¹ãŠéè²ããªãããšã確èªãããéå£æ§è©Šéšããšããæ¹æ³ã§æ€èšããŠãããšããããšã§ããâ ããã¯æåŸ
ãããã
éçºããã§ã«ã¯ã¯ãã³ãåããæ¹ãå€ããããæ¢åã®ã«æ¯ã¹ãŠå£ãããªããã®éå£å¢è©Šéšãããã ãšã
NHKãã¥ãŒã¹
åœç£ã¯ã¯ã㳠第äžäžå
± 幎å
ã«ãæ°å人èŠæš¡ã®èšåºè©Šéšå®æœãž
åé¡ã¯è³ªããâŠãã¯ã¯ãã³ã«ãè²ã
ãã£ãŠããã¡ã€ã¶ãŒè£œã®ã¯ãã¡ã€ã¶ãŒèªèº«ãé©ãã»ã©è¯ãã£ãããããåœç£ã¯ã¯ãã³ããã®æ°Žæºã§ã§ããããããâŠããã®åé¡ãã¡ãããšè°è«ãããªããšããã£ãŠæ··ä¹±ãããã
第äžäžå
±ãç±ç°ãã€ãªããžã¯ã¹ãã¢ã³ãžã§ã¹ãå¡©é矩ãKMãã€ãªããžã¯ã¹
å©æš©ã®éŠããããä»è
ãšã¯éã£ãŠç¬¬äžäžå
±ã¯ç§åŠçãªåŽé¢(éå£æ§è©Šéš)ããç«èšŒããããšããŠããæãéåžžã«ä¿¡é Œã§ããŸããæ¥æ¬ãšããŠãïœRNAã¯ã¯ãã³ã®æè¡ãç²åŸããŠããã°ä»åŸã®æªç¥ã®ãŠã€ã«ã¹ãžã®å¯Ÿçã«å€§ããè²¢ç®ãããšæãããŸããæéã¯ããããå¿æŽããŸãã
åœç£ã®mRNAã¯ã¯ãã³ãšãªãâŠäœã ã£ããèšåºè©Šéšã«åå ããŠããããããã ããã©ããã£ããåå ã§ããã®ïŒ ïŒ
ããåŸ
ã£ãŠã人ãå±
ããåãæ¢ããæ²»éšãããªãåããã人ã¯ååããã£ãŠ
ç¥ã®åŽ©å£
ç¥ã®åŽ©å£
ãã®æè¡ã¯æ¥æ¬ã§ãæã£ãŠããããããã
ãæ°å人èŠæš¡ã®èšåºè©Šéšã幎å
ã«ãå®æœã
被éšè ã¯ã©ã調éïŒ
â é
â¡åŸæ¥å¡ã«å§å
â¢ååè
ãããããæãä»ããªã
被éšè ã¯ã©ã調éïŒ
â é
â¡åŸæ¥å¡ã«å§å
â¢ååè
ãããããæãä»ããªã
æ°åã³ããã¯ã¯ãã³ãéçºããŠããåœå
ã¡ãŒã«ãŒã§ã¯ããããŸã§ã«4瀟ãéçºäžã®ã¯ã¯ãã³ãããã«æäžããèšåºè©Šéšãè¡ã£ãŠãããšã®ããšã§ãã
ãã¡ãã®ãã¥ãŒã¹ã®å人èŠæš¡ã¯åèçãšé¢ä¿ã¯ãªãã®ã§ãããæ¥æ¬ã¯ãããããè²ã
ãªå·®å¥ãç¶ãããã§ãããå·®å¥ããããªããã§ããããã©ã³ã¹ãžã§ã³ã㌠ã人皮差å¥ãç¶ãããã§ããã
ãã¡ãã®NHKãã¥ãŒã¹ãšåèçé¢ä¿ã®äºæ
ã®NHKãã¥ãŒã¹ã¯ãã©ã³ã¹ãžã§ã³ã㌠ã人皮差å¥ãšåããããªå·®å¥ãã¯ã¯ãã³å·®å¥ãšãåèçå·®å¥ãããŠããªããšæããŸããããã¡ãã®åé¡å©ãããã人ããŸããã
Daiichi Sankyo aiming to start distributing first domestic mRNA vaccine by end of this year
åŸçºãªãã§ã¯ã®èª²é¡ãããããã ãé·æçã«ã¯ããæ¹åæ§ã ãšæããå¿æŽãããã
åœå
ã§äœããããšã«ã¯æå³ãããã®ã§é 匵ã£ãŠæ¬²ããã
å人çã«ã¯ãæ°ããææçã¯5ïœ10幎ã®ãã¡ã«å¿
ãã©ããããã§çºçãããšæã£ãŠããã®ã§ãçç£äœå¶ãæã£ãŠããããšã匷ã¿ã«ãªãã
æ¥çš®ãããšããã
第äžäžå
± ã³ããã¯ã¯ãã³mRNAã¿ã€ããªã®ã§ããã¡ã€ã¶ãŒãã¢ãã«ããããã®æå¹çãã
幎å ã«ãæ°å人èŠæš¡ã®èšåºè©Šéšå®æœãž | æ°åã³ãã ã¯ã¯ãã³ïŒæ¥æ¬åœå ïŒ
幎å ã«ãæ°å人èŠæš¡ã®èšåºè©Šéšå®æœãž | æ°åã³ãã ã¯ã¯ãã³ïŒæ¥æ¬åœå ïŒ
ìŒë³ž ì ìœì¬ ë€ìŽìŽì°ì°ì¿ ì°ëŽ mRNA ìœë¡ë ë°±ì ìììí NHKìë ì묞ëŽì€ Japan firm preparing large COVID-19 vaccine trial
Japan firm preparing large COVID-19 vaccine trial
åœç£ã¯ã¯ãã³ãåŸ
ã£ãŠãã人ã«ã¯æ¯éãã®éå£æ§è©Šéšã«åå ããŠè²°ãã°ããã®ã§ã¯ãæ¥å¹ŽããããŒã¹ã¿ãŒæ¥çš®ãå¿
èŠã«ãªããããããªãããåœç£mRNAã¯ã¯ãã³ãåºæ¥ãã®ã¯å€§æè¿ãã€ã³ãã«ãä»ã®ã¯ã¯ãã³ã«ãæè¡ãæµçšãããšãããŸãæ°çš®ã®ææçã®æã®ç«ã¡äžããã«ãå®å¿ã
åœå
補ã®mRNAã¯ã¯ãã³ãäžæããããšãããã©ã
ã¯ãŠãã®ã»ãïŒ
ãªãã«ã¯ Wilde:
ã³ãã察çã®å®å®åã«åããŠãæå ±ã ãšæããâ
第äžäžå
±ã¯
åœç£ã®ãmRNAã¯ã¯ãã³ãã®
æ°å人èŠæš¡ã®èšåºè©Šéšãã
幎å ã«ãå®æœããæ¹åã§
æºåãé²ããŠããããšãåãããŸãã
詳ããã¯ãã¡ãã§ãâ
åœç£ã®ãmRNAã¯ã¯ãã³ãã®
æ°å人èŠæš¡ã®èšåºè©Šéšãã
幎å ã«ãå®æœããæ¹åã§
æºåãé²ããŠããããšãåãããŸãã
詳ããã¯ãã¡ãã§ãâ
ãããŸã¯æ°åã³ãããæåªå
ã ããä»åŸã»ãã®ã¯ã¯ãã³ãéºäŒåæ²»çãããé åã§ãéçºãæšé²ããŠããããã
èšåºè©Šéšããã«å¢ç£äœå¶ã¢ããŒã«ã°ããããå¡©é矩ã®å§¿å¢ãããããã
以åãŸãã«ãŒã¶ã§ãã¡ãã£ã¢ã§ãšã€ã·ã§ããåéãããŠãããªã
以åãŸãã«ãŒã¶ã§ãã¡ãã£ã¢ã§ãšã€ã·ã§ããåéãããŠãããªã
第äžäžå
±ã¯ã¡ãããšã«ãŒã«ã«åã£ãŠããã®ããå¡©é矩èŠãŠããïŒä¿¡é ŒãããäŒæ¥ã£ãŠããèšãã®ã ã
ããã«ããŠãã¢ã³ãžã§ã¹ãæªã ã«åãäžããNHKã¯ãã«ãïŒ
ããã«ããŠãã¢ã³ãžã§ã¹ãæªã ã«åãäžããNHKã¯ãã«ãïŒ
ããã䜿ãããé ã«ã¯åæ°ä»¥äžãïŒã7å²äœã®äººã¯æã¡çµãã£ãŠããð€
åœç£ã ãããã£ãŠçç±ã§æã€äººãããããã ãã©ã
åœç£ã ãããã£ãŠçç±ã§æã€äººãããããã ãã©ã
ããŒã¹ã¿ãŒå¹æçãããã§ã
æ²»éšåéããã®ã解ãããã©åå åºæ¥ã人ã¯ã¬ã³ã¬ã³åäžããŠãããŠãª
å¿è«ãæç ãšãäœèª¿ãšãè«žã 倧äžå€«ãªäººãã¡
å¿è«ãæç ãšãäœèª¿ãšãè«žã 倧äžå€«ãªäººãã¡
5Gã«ã€ãªããããã«ãªããªãã¹ããåžå Žãçµããããã²ãŒã ãã§ã³ãžã£ãŒãªãã ãã©
åœç£ã¯ã¯ãã³ãéçºã§ããããšã¯éèŠãªã®ã§é 匵ã£ãŠã»ããã
第äžäžå
±ã¯æ¥æ¬ç£ã®mRNAã¯ã¯ãã³ãéçºäžãšã®ããšãèšåºè©Šéšããã©ã»ãã§ãªãæ¢åã¯ã¯ãã³ãšã®æ¯èŒã§ããéå£æ§è©Šéšã§è¡ãããã§ããéã«åãã®ããšããçåã¯ãããŸãããåœç£ã¯ã¯ãã³ä»ç€Ÿããã¯çŸå®çãªã¢ãããŒãã®ããã«æããŸãã茞åºãããŒã¹ã¿ãŒå©çšã§ããããã
åœç£ã®mRNAã¯ã¯ãã³ãã
2022幎床ã®å®çšåãé·äžå Žã ããã
åœç£ã«æåŸ
ããŸã
èšåºè©Šéšå®æœãž
èšåºè©Šéšå®æœãž
åœå
ã§ã®ã¯ã¯ãã³éç£äœå¶ã¯äœãã«ããŠãå¿
èŠãªããšãªã®ã§ããããäžæãè¡ã£ãŠãããã°è¯ãããïŒ
mRNAã¯å¿çšã®å©ãæè¡ãªã®ã§åœå
ã§ãæè¡ã確ä¿ããŠããã®ã¯ããããšãã©ãããšéã£ãŠãã¡ãã¯ä¿¡çšã§ãããã ã
è¯ãããšã ãšæãããã¡ã€ã¶ãŒãããªã³ããã¯ã®ç¬¬äžçžè©Šéšã¯æ°äžäººãªã®ã§èŠå£ããããã©ç¬¬äžåŒŸãšããŠã¯å·²ãåŸãªãæ°ãšæããä»ç€Ÿãããã ãã©ãåœéå±éãããªãä»åœã§ã第äžçžè©ŠéšããŠããããšã§ç©ã¿å¢ãããŠããã
æ°åã³ãããŠã€ã«ã¹ã§ã¯ãã§ã«å®çšåãããã¯ã¯ãã³ãããããšãããã¯ã¯ãã³ãå«ãŸããŠããªãåœã®è¬ãæ°äžäººã«æäžããŠå¹æãæ¯èŒãã倧èŠæš¡ã¯èšåºè©Šéšã¯å«ççã«é£ãããšãããŠããŸãã
ãã®ããäŒç€Ÿã§ã¯ãéå£æ§è©Šéšããšããæ¹æ³ã§æ€èšããŠãããšããããšã§ãã
ãã®ããäŒç€Ÿã§ã¯ãéå£æ§è©Šéšããšããæ¹æ³ã§æ€èšããŠãããšããããšã§ãã
éçºäžã®ã¯ã¯ãã³ãæäžãã人ã®æäœã®å€ããã§ã«å®çšåãããã¯ã¯ãã³ãšæ¯ã¹ãŠéè²ããªãããšã確èªãããéå£æ§è©Šéšããšããæ¹æ³ã§æ€èšããŠãããšããããšã§ãã
ITç£æ¥ããæ©ãå»è¬ãæ¥ã®äžž5Gãå®çšå(æä¹±)
ä»ç€Ÿãçã£åœãªè©Šéšãããšãªã£ããå¡©é矩ãæ¹é転æãããããâŠã:
ã»ãŒãŒãŒ
mRNAã¯ã¯ãã³ãããã€ã³ãã«ã¿ããã«åŒ±æ¯åããããŠã€ã«ã¹ãæäžã£ãŠã§ããªãã®ïŒïŒ
mRNAã¯ã¡ãšæã
mRNAã¯ã¡ãšæã
äœã§æ害説ãšå¯åå¿ãªã³ãã¬ãŒãã§æåŠãã人ãå€ããéºäŒåçµã¿æãã¿ã€ããªãã ãããïŒ
ã€ãããªæ¥æ¬ã¯ã€ãã«ã¡ã¯ãã³é Œã¿ãããªãããã§ããïŒ
ã€ãããªæ¥æ¬ã¯ã€ãã«ã¡ã¯ãã³é Œã¿ãããªãããã§ããïŒ
ããæã¡ãŸãã£ãŠãã®ã«èšåºå®éšã£ãŠïŒïŒïŒ
å㞠次ãž